MA41415A - Dinucléotides cycliques utiles pour traiter, entre autres, le cancer - Google Patents
Dinucléotides cycliques utiles pour traiter, entre autres, le cancerInfo
- Publication number
- MA41415A MA41415A MA041415A MA41415A MA41415A MA 41415 A MA41415 A MA 41415A MA 041415 A MA041415 A MA 041415A MA 41415 A MA41415 A MA 41415A MA 41415 A MA41415 A MA 41415A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- treating
- cyclic dinucleotides
- useful
- dinucleotides useful
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501462.4A GB201501462D0 (en) | 2015-01-29 | 2015-01-29 | Novel compounds |
| US201562262621P | 2015-12-03 | 2015-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41415A true MA41415A (fr) | 2017-12-05 |
Family
ID=52705427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041415A MA41415A (fr) | 2015-01-29 | 2016-01-26 | Dinucléotides cycliques utiles pour traiter, entre autres, le cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10047115B2 (fr) |
| EP (1) | EP3250573A1 (fr) |
| JP (1) | JP6722682B2 (fr) |
| KR (1) | KR20170102362A (fr) |
| CN (1) | CN107108684B (fr) |
| AU (1) | AU2016212085B2 (fr) |
| BR (1) | BR112017016006A2 (fr) |
| CA (1) | CA2973806A1 (fr) |
| CL (1) | CL2017001932A1 (fr) |
| CO (1) | CO2017007293A2 (fr) |
| CR (1) | CR20170350A (fr) |
| DO (1) | DOP2017000175A (fr) |
| EA (1) | EA031728B1 (fr) |
| GB (1) | GB201501462D0 (fr) |
| IL (1) | IL252935A0 (fr) |
| MA (1) | MA41415A (fr) |
| MX (1) | MX2017009837A (fr) |
| PE (1) | PE20171322A1 (fr) |
| PH (1) | PH12017501233A1 (fr) |
| SG (1) | SG11201705077VA (fr) |
| WO (1) | WO2016120305A1 (fr) |
| ZA (1) | ZA201704732B (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| AU2014260015B2 (en) | 2013-04-29 | 2019-11-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10450341B2 (en) * | 2014-06-04 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of STING |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| PE20180688A1 (es) * | 2015-08-13 | 2018-04-23 | Merck Sharp & Dohme | Compuestos di-nucleotidos ciclicos como agonistas de sting |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| UY36969A (es) * | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
| EP3322713B1 (fr) | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Dinucléotides cycliques de purine à titre de modulateurs du sting |
| AU2017207757B2 (en) | 2016-01-11 | 2021-05-27 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| SG11201807660QA (en) | 2016-03-18 | 2018-10-30 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| US10696985B1 (en) | 2016-06-06 | 2020-06-30 | Vanderbilt University | Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| KR102569881B1 (ko) | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
| US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| CA3047113A1 (fr) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Agonistes dinucleotidiques cycliques de sting pour le traitement du cancer |
| US11021511B2 (en) | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| ES2924186T3 (es) * | 2017-01-27 | 2022-10-05 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de STING |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| US10933078B2 (en) | 2017-02-21 | 2021-03-02 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
| WO2018208667A1 (fr) * | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques en tant qu'agonistes sting |
| JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| AU2018311966A1 (en) * | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
| MX2020002303A (es) * | 2017-08-30 | 2020-09-10 | Beijing Xuanyi Pharmasciences Co Ltd | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
| EP3676279B1 (fr) | 2017-08-31 | 2021-12-01 | Bristol-Myers Squibb Company | Dinucléotides cycliques utilisés en tant qu'agents anticancéreux |
| JP7316263B2 (ja) * | 2017-08-31 | 2023-07-27 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| KR102651946B1 (ko) * | 2017-08-31 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| WO2019051488A1 (fr) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| WO2019051489A1 (fr) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| WO2019084060A1 (fr) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugués et leurs procédés d'utilisation pour l'administration sélective d'agents immunomodulateurs |
| TW201922263A (zh) | 2017-11-10 | 2019-06-16 | 日商武田藥品工業股份有限公司 | 干擾素基因刺激蛋白之調節化合物，及製造和使用方法 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| EP3727401A4 (fr) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
| CN110016025B (zh) * | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN110272462B (zh) * | 2018-03-15 | 2023-03-10 | 南开大学 | 制备化合物的方法 |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| EP4242212A3 (fr) | 2018-03-23 | 2023-11-15 | Takeda Pharmaceutical Company Limited | Composés modulateurs de sting avec liaisons sulfamate, et procédés de fabrication et d'utilisation |
| IL309265A (en) | 2018-03-23 | 2024-02-01 | Codiak Biosciences Inc | Extracellular vesicles containing agonist-STING |
| US20210009627A1 (en) | 2018-03-27 | 2021-01-14 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]trizain-7-one as string agonists |
| JP2021519279A (ja) | 2018-03-27 | 2021-08-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾環式ジヌクレオチド化合物 |
| EP3774765A4 (fr) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
| JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| EP3802534B1 (fr) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Composés hétérocycliques tricycliques en tant qu'activateurs de sting |
| AU2019277679A1 (en) | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
| WO2020010451A1 (fr) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Amides imidazolyle hétéroaromatiques fusionnés, compositions et utilisations de ceux-ci en tant qu'agonistes de sting |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020028565A1 (fr) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Composés hétéroaryles tricycliques en tant qu'activateurs de sting |
| CA3099904A1 (fr) | 2018-08-16 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Sels de composes et cristaux de ceux-ci |
| EP3841112A1 (fr) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
| US20200113912A1 (en) | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
| WO2020057546A1 (fr) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation |
| US20220008346A1 (en) | 2018-10-30 | 2022-01-13 | Vanderbilt University | Graft copolymers, methods of forming graft copolymers, and methods of use thereof |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| CA3131620A1 (fr) * | 2019-03-05 | 2020-09-10 | F-star Therapeutics, Inc. | Composes, compositions et procedes pour le traitement d'une maladie |
| US20220168415A1 (en) | 2019-03-21 | 2022-06-02 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
| WO2020205323A1 (fr) * | 2019-03-29 | 2020-10-08 | Merck Sharp & Dohme Corp. | Formulations stables de composés agonistes de sting à base de dinucléotides cycliques et leurs méthodes d'utilisation |
| US20220177465A1 (en) | 2019-04-04 | 2022-06-09 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| JP2022531899A (ja) | 2019-05-09 | 2022-07-12 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| CA3139809A1 (fr) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Conjugues anticorps-medicament |
| US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202120500A (zh) | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途 |
| EP3789393A1 (fr) * | 2019-09-06 | 2021-03-10 | Centre National de la Recherche Scientifique | Inhibiteurs de piqûre et leurs utilisations thérapeutiques |
| EP4034276A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| EP4034150A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Agoniste de sting comprenant des exosomes combinés à l'il-12 présentant des exosomes pour le traitement d'une tumeur |
| US20240099973A1 (en) | 2019-09-25 | 2024-03-28 | Lonza Sales Ag | Extracellular vesicle compositions |
| WO2021067644A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
| WO2021113679A1 (fr) | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Composés dimères utilisés en tant qu'agonistes de sting |
| EP4106819A1 (fr) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
| EP4117717A1 (fr) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Vésicules extracellulaires pour le traitement de troubles neurologiques |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| WO2022006327A1 (fr) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Conjugués d'anticorps anti-asgr1 et leurs utilisations |
| WO2022032191A1 (fr) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie |
| EP4216993A2 (fr) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
| WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
| WO2022097117A1 (fr) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Conjugués anticorps-médicament |
| WO2023056468A1 (fr) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Vésicule extracellulaire comprenant un agoniste de sting marqué au cholestérol |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| EP1645561A1 (fr) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Procede de synthese d'un bisdinucleoside cyclique |
| WO2005030186A2 (fr) | 2003-07-28 | 2005-04-07 | Univ Maryland | Procede permettant d'attenuer la virulence d'agents pathogenes microbiens et d'inhiber la formation d'un biofilm microbien |
| US20050187278A1 (en) | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| WO2005087238A2 (fr) | 2004-03-15 | 2005-09-22 | Karaolis David K R | Technique de stimulation de reponse immune, inflammatoire ou neuroprospective |
| EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
| WO2009133560A1 (fr) | 2008-04-29 | 2009-11-05 | Smart Assays | Dérivés de bis-(nucléotide monophosphate) cycliques non hydrolysables et perméables et leurs utilisations |
| WO2013166000A1 (fr) | 2012-04-30 | 2013-11-07 | Barber Glen N | Modulation de réponses immunitaires |
| US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
| WO2012149307A2 (fr) | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Vaccins à base de longs peptides synthétiques (slp) |
| WO2013086331A1 (fr) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | Cyclase di-nucléotide à haute efficacité |
| JP5650780B2 (ja) | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | ワクチン組成物 |
| US9770467B2 (en) | 2012-06-08 | 2017-09-26 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| US20140170689A1 (en) | 2012-12-12 | 2014-06-19 | The Research Foundation For The State University Of New York | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| ES2678194T3 (es) | 2012-12-19 | 2018-08-09 | Board Of Regents, The University Of Texas System | Determinación farmacéutica de una vía de señalización de dinucleótido cíclico de mamífero |
| AU2014260015B2 (en) * | 2013-04-29 | 2019-11-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| WO2015017652A1 (fr) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Cristaux sting et modulateurs associés |
| EP3071209A4 (fr) | 2013-11-19 | 2017-08-16 | The University of Chicago | Utilisation d'un agoniste de sting en tant que traitement anti-cancéreux |
| EP3071229A4 (fr) | 2013-11-22 | 2017-05-10 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| US10421971B2 (en) | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| EP3148566B1 (fr) | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Peptides longs synthétiques (slp) à des fins de vaccination thérapeutique contre l'infection par le virus de l'hépatite b |
| US10450341B2 (en) * | 2014-06-04 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of STING |
| US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
| WO2016096577A1 (fr) | 2014-12-16 | 2016-06-23 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| EP3546473A1 (fr) | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Dinucléotides cycliques pour l'induction de la cytokine |
| CN112626153A (zh) | 2014-12-17 | 2021-04-09 | 立博美华基因科技有限责任公司 | 用cGAMP或cGAsMP治疗癌症的方法 |
| US20180000906A1 (en) | 2015-01-16 | 2018-01-04 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016123573A1 (fr) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Matériaux péritumoraux et intratumoraux pour traitement anticancéreux |
| US20160220652A1 (en) | 2015-02-03 | 2016-08-04 | Advaxis, Inc. | Methods of using recombinant listeria vaccine strains in disease immunotherapy |
| CA3014427A1 (fr) | 2015-02-13 | 2016-08-18 | Icahn School Of Medicine At Mount Sinai | Compositions contenant de l'arn et leurs methodes d'utilisation |
| JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| PE20180688A1 (es) | 2015-08-13 | 2018-04-23 | Merck Sharp & Dohme | Compuestos di-nucleotidos ciclicos como agonistas de sting |
| UY36969A (es) | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
-
2015
- 2015-01-29 GB GBGB1501462.4A patent/GB201501462D0/en not_active Ceased
-
2016
- 2016-01-26 MA MA041415A patent/MA41415A/fr unknown
- 2016-01-27 PE PE2017001269A patent/PE20171322A1/es not_active Application Discontinuation
- 2016-01-27 KR KR1020177022778A patent/KR20170102362A/ko unknown
- 2016-01-27 JP JP2017539658A patent/JP6722682B2/ja not_active Expired - Fee Related
- 2016-01-27 CN CN201680006178.4A patent/CN107108684B/zh not_active Expired - Fee Related
- 2016-01-27 SG SG11201705077VA patent/SG11201705077VA/en unknown
- 2016-01-27 CA CA2973806A patent/CA2973806A1/fr not_active Abandoned
- 2016-01-27 CR CR20170350A patent/CR20170350A/es unknown
- 2016-01-27 BR BR112017016006A patent/BR112017016006A2/pt not_active Application Discontinuation
- 2016-01-27 WO PCT/EP2016/051654 patent/WO2016120305A1/fr active Application Filing
- 2016-01-27 EP EP16702069.2A patent/EP3250573A1/fr not_active Withdrawn
- 2016-01-27 MX MX2017009837A patent/MX2017009837A/es unknown
- 2016-01-27 US US15/543,007 patent/US10047115B2/en not_active Expired - Fee Related
- 2016-01-27 AU AU2016212085A patent/AU2016212085B2/en not_active Ceased
- 2016-01-27 EA EA201791607A patent/EA031728B1/ru not_active IP Right Cessation
-
2017
- 2017-06-15 IL IL252935A patent/IL252935A0/en unknown
- 2017-07-03 PH PH12017501233A patent/PH12017501233A1/en unknown
- 2017-07-13 ZA ZA2017/04732A patent/ZA201704732B/en unknown
- 2017-07-21 CO CONC2017/0007293A patent/CO2017007293A2/es unknown
- 2017-07-28 DO DO2017000175A patent/DOP2017000175A/es unknown
- 2017-07-28 CL CL2017001932A patent/CL2017001932A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017009837A (es) | 2018-02-09 |
| CO2017007293A2 (es) | 2017-10-31 |
| JP6722682B2 (ja) | 2020-07-15 |
| GB201501462D0 (en) | 2015-03-18 |
| IL252935A0 (en) | 2017-08-31 |
| US20180002369A1 (en) | 2018-01-04 |
| EP3250573A1 (fr) | 2017-12-06 |
| KR20170102362A (ko) | 2017-09-08 |
| PH12017501233A1 (en) | 2017-10-30 |
| SG11201705077VA (en) | 2017-07-28 |
| CN107108684B (zh) | 2020-08-21 |
| CL2017001932A1 (es) | 2018-02-16 |
| ZA201704732B (en) | 2019-02-27 |
| EA031728B1 (ru) | 2019-02-28 |
| PE20171322A1 (es) | 2017-09-11 |
| WO2016120305A1 (fr) | 2016-08-04 |
| DOP2017000175A (es) | 2017-09-15 |
| CA2973806A1 (fr) | 2016-08-04 |
| BR112017016006A2 (pt) | 2018-03-20 |
| AU2016212085A1 (en) | 2017-07-20 |
| JP2018507192A (ja) | 2018-03-15 |
| EA201791607A1 (ru) | 2018-01-31 |
| CN107108684A (zh) | 2017-08-29 |
| AU2016212085B2 (en) | 2018-06-14 |
| US10047115B2 (en) | 2018-08-14 |
| CR20170350A (es) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41415A (fr) | Dinucléotides cycliques utiles pour traiter, entre autres, le cancer | |
| HK1251407A1 (zh) | 治療癌症的方法 | |
| DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
| DK3365373T3 (da) | Bindingsmolekyler, der hæmmer cancervækst | |
| SI3785717T1 (sl) | Postopki za zdravljenje okužb s Coronaviridae | |
| BR112017023853A2 (pt) | composições de nanopartícula para terapia sustentada. | |
| IL265335A (en) | Treating cluster headache | |
| BR112018005409A2 (pt) | terapêutica de glicodirecionamento. | |
| HK1254258A1 (zh) | 使用阿吡莫德治療癌症的方法 | |
| HK1250944A1 (zh) | 用於治療癌症的方法 | |
| IL249936A0 (en) | Methods for treating hypotension | |
| BR112016029236A2 (pt) | métodos para tratar prurido. | |
| IL246558A0 (en) | New methods of cancer treatment | |
| HK1250942A1 (zh) | 用於治療癌症的方法 | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| HK1250943A1 (zh) | 用於治療癌症的方法 | |
| GB201519450D0 (en) | Novel treatment | |
| ES1145159Y (es) | Aparato para eliminar piojos. | |
| BR112016026476A2 (pt) | Bloco de corrente | |
| DK3250774T3 (da) | Port, især hurtigt løbende port | |
| DK3795130T3 (da) | Terapiapparat. | |
| IL249616A0 (en) | Methods for treating inflammation | |
| DK3250168T3 (da) | Forbedringer vedrørende nethindebehandling | |
| GB2536058B (en) | Guide block | |
| HK1256371A1 (zh) | 用於治療腫瘤的方法 |